147 related articles for article (PubMed ID: 26324075)
21. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Olaussen KA; Commo F; Tailler M; Lacroix L; Vitale I; Raza SQ; Richon C; Dessen P; Lazar V; Soria JC; Kroemer G
Oncogene; 2009 Dec; 28(48):4249-60. PubMed ID: 19749798
[TBL] [Abstract][Full Text] [Related]
22. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.
Simbulan-Rosenthal CM; Dakshanamurthy S; Gaur A; Chen YS; Fang HB; Abdussamad M; Zhou H; Zapas J; Calvert V; Petricoin EF; Atkins MB; Byers SW; Rosenthal DS
Oncotarget; 2017 Feb; 8(8):12576-12595. PubMed ID: 28157711
[TBL] [Abstract][Full Text] [Related]
23. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
[TBL] [Abstract][Full Text] [Related]
24. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
25. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.
Yee PS; Zainal NS; Gan CP; Lee BKB; Mun KS; Abraham MT; Ismail SM; Abdul Rahman ZA; Patel V; Cheong SC
Target Oncol; 2019 Apr; 14(2):223-235. PubMed ID: 30806895
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
[TBL] [Abstract][Full Text] [Related]
27. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
28. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
29. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
30. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
32. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
[TBL] [Abstract][Full Text] [Related]
33. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
34. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
36. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
37. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells.
Geng R; Tan X; Zuo Z; Wu J; Pan Z; Shi W; Liu R; Yao C; Wang G; Lin J; Qiu L; Huang W; Chen S
Chin J Cancer; 2017 Jul; 36(1):63. PubMed ID: 28756770
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of the PET Tracer
Pratt EC; Isaac E; Stater EP; Yang G; Ouerfelli O; Pillarsetty N; Grimm J
J Nucl Med; 2020 Dec; 61(12):1845-1850. PubMed ID: 32444378
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]